Halcyon 4.0 for Cone Beam CT
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using Cone-Beam CT imaging in radiation therapy planning. The goal is to determine if images from the Halcyon 4.0 machine (a type of imaging device) match the quality of those from the standard CT simulator for planning radiation treatments. It targets patients at the Perelman Center with specific cancers, such as breast or head-and-neck cancer, who already have a complete set of treatment plans. As an unphased trial, this study allows patients to contribute to advancements in imaging technology that could enhance future cancer treatment planning.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the Halcyon 4.0 for Cone Beam CT is safe for radiation therapy treatment simulation?
Research has shown that the Halcyon system, which includes a special imaging type called Cone Beam CT (CBCT), has undergone safety testing in medical settings. In one study, 760 patients received radiation therapy using the Varian Halcyon system. Researchers checked 16,958 measurements and found no major safety problems, suggesting the system is generally well-tolerated.
The Halcyon system aims to make radiation therapy more efficient without compromising safety. It provides treatment quickly while ensuring patient comfort and safety. Although detailed information on side effects is limited, available evidence indicates the system is generally safe for use in medical settings.
This information is based on past studies and ongoing research. Always consult a healthcare professional if there are concerns before joining a clinical trial.12345Why are researchers excited about this trial?
Researchers are excited about the Halcyon 4.0 for Cone Beam CT (CBCT) because it promises to enhance radiotherapy treatment planning. Unlike traditional CT simulators, the Halcyon 4.0 aims to deliver CBCT images that are comparable in quality, potentially streamlining the treatment process by using a single machine for imaging and therapy. This could lead to more accurate and efficient radiotherapy dose calculations, ultimately improving patient outcomes by personalizing treatment for malignancies across various disease sites.
What evidence suggests that the Halcyon 4.0 is effective for Cone-Beam CT imaging in radiation therapy?
Research shows that the Halcyon 4.0 system can enhance radiotherapy accuracy by using Cone-Beam CT (CBCT) imaging. Studies have found that it positions patients more precisely, which is crucial for effective radiation treatment. This trial compares the Halcyon 4.0 to standard CT scans to confirm its effectiveness in planning radiation treatments. The Halcyon 4.0 can also reduce radiation exposure to healthy tissues by up to 50% with certain imaging methods. Overall, the Halcyon 4.0 appears promising in making radiotherapy safer and more precise.14678
Who Is on the Research Team?
Michelle Alonso-Basanta, MD, PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are set to receive external beam radiotherapy at the Perelman Center for cancers like head-and-neck, thoracic, breast, gastrointestinal, gynecologic or genitourinary. They must understand the study and consent to it. A full treatment plan with CT images and radiation prescriptions is required.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo standard of care radiation therapy with novel CBCT imaging for treatment simulation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Halcyon 4.0
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester